{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:27:12Z","timestamp":1793114832922,"version":"4.5.0"},"reference-count":172,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007289","name":"Nanjing Medical University","doi-asserted-by":"publisher","award":["KY1020001"],"award-info":[{"award-number":["KY1020001"]}],"id":[{"id":"10.13039\/501100007289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.seminoncol.2025.152399","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T12:46:29Z","timestamp":1755693989000},"page":"152399","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Application prospects of tumor vaccines for pancreatic cancer: From TAAs to TSAs and combination strategies"],"prefix":"10.1016","volume":"52","author":[{"given":"Zerui","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1109-1740","authenticated-orcid":false,"given":"Xinjian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seminoncol.2025.152399_bib0001","first-page":"12","article-title":"Cancer statistics","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0002","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8+T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0003","article-title":"Tumor mutational burden in real - world patients with pancreatic cancer: genomic alterations and predictive value for immune checkpoint inhibitor effectiveness","volume":"7","author":"Quintanilha","year":"2023","journal-title":"JCO Prec Oncol"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0004","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1080\/1744666X.2022.2120471","article-title":"Combination immunotherapy for pancreatic cancer: challenges and future considerations","volume":"18","author":"G\u00f6ssling","year":"2022","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.576399","article-title":"Stroma - targeting therapy in pancreatic cancer: one coin with two sides?","volume":"10","author":"Jiang","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0006","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/2646148","article-title":"Epithelial - mesenchymal transition in pancreatic cancer: a review","author":"Wang","year":"2017","journal-title":"BioMed research international"},{"issue":"72","key":"10.1016\/j.seminoncol.2025.152399_bib0007","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cytogfr.2023.06.006","article-title":"Targeting the metabolism and immune system in pancreatic ductal adenocarcinoma: insights and future directions","volume":"71","author":"Bandi","year":"2023","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0008","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/jnci\/djae095","article-title":"Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C - mutated disease","volume":"116","author":"Keane","year":"2024","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0009","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/MPA.0b013e31823e3632","article-title":"Vascular invasion in pancreatic cancer: predictive values for endoscopic ultrasound and computed tomography imaging","volume":"41","author":"Tellez-Avila","year":"2012","journal-title":"Pancreas"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0010","series-title":"PDQ cancer information summaries","article-title":"Pancreatic cancer treatment (PDQ\u00ae): health professional version","year":"2025"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0011","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.20.00590","article-title":"Randomized phase III trial of pegvorhyaluronidase Alfa with Nab-Paclitaxel plus Gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma","volume":"38","author":"Van Cutsem","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0012","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1200\/JCO.18.01295","article-title":"Phase IB\/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313","volume":"37","author":"Ramanathan","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0013","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/MPA.0b013e31816a4a33","article-title":"PDX-1 acts as a potential molecular target for treatment of human pancreatic cancer","volume":"37","author":"Liu","year":"2008","journal-title":"Pancreas"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0014","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.18632\/oncotarget.1890","article-title":"CHIP is a novel tumor suppressor in pancreatic cancer through targeting EGFR","volume":"5","author":"Wang","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0015","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/s41401-020-00584-2","article-title":"Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications","volume":"42","author":"Hu","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0016","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004485","article-title":"Detection of microsatellite instability - high (MSI - H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer","volume":"10","author":"Chakrabarti","year":"2022","journal-title":"J. Immunother. Cancer."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0017","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/gutjnl-2020-320726","article-title":"Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications","volume":"70","author":"Luchini","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1458517","article-title":"Case report: achieving significant tumor reduction in advanced pancreatic adenocarcinoma","volume":"14","author":"Liu","year":"2024","journal-title":"Frontiers in oncology"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0019","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ccell.2024.03.009","article-title":"The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia","volume":"42","author":"Liu","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0020","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.12688\/f1000research.11371.1","article-title":"Novel biomarkers and endoscopic techniques for diagnosing pancreaticobiliary malignancy","volume":"6","author":"Keane","year":"2017","journal-title":"F1000Res"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0021","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ccell.2024.09.010","article-title":"The hallmarks of cancer immune evasion","volume":"42","author":"Galassi","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0022","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41577-022-00796-z","article-title":"TGF\u03b2 control of immune responses in cancer: a holistic immuno-oncology perspective","volume":"23","author":"Nixon","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0023","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11302-019-09676-z","article-title":"Role of purines in regulation of metabolic reprogramming","volume":"15","author":"Tang","year":"2019","journal-title":"Purinergic Signal"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0024","doi-asserted-by":"crossref","first-page":"156","DOI":"10.33160\/yam.2018.09.002","article-title":"Evaluation of a program of clean intermittent catheterization for underactive bladder after radical hysterectomy","volume":"61","author":"Hikita","year":"2018","journal-title":"Yonago Acta Med"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0025","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2174\/1568009622666220214103533","article-title":"Cancer vaccine in cold tumors: clinical landscape, challenges, and opportunities","volume":"22","author":"Rezaei","year":"2022","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1344272","article-title":"Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors","volume":"15","author":"Ouyang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0027","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","article-title":"Cancer vaccines as promising immuno-therapeutics: platforms and current progress","volume":"15","author":"Liu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0028","article-title":"Recent advances in cancer vaccines: challenges, achievements, and futuristic prospects","author":"Gupta","year":"2022","journal-title":"Vaccines 10, 2011"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0029","article-title":"A neoantigen-based peptide vaccine for patients with advanced pancreatic cancer refractory to standard treatment","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0030","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold tumors: a therapeutic challenge for","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Immunothera. Front. Immunol."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0031","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-024-01111-8","article-title":"Cancer immune evasion, immunoediting and intratumour heterogeneity","author":"Roerden","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0032","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41375-020-0792-2","article-title":"CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression","volume":"35","author":"Fousek","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0033","article-title":"Construction and characterization of a novel secreted MsC - CAR - T cell in solid tumors","volume":"611","author":"Mao","year":"2024","journal-title":"Cancer Lett"},{"issue":"6 \u2013 Sup","key":"10.1016\/j.seminoncol.2025.152399_bib0034","first-page":"7","article-title":"Abstract 4094: immune modulatory cancer vaccines against IDO1 and PD - L1 trigger distinct pathways and cooperatively reduce tumor growth in preclinical models","volume":"84","author":"Chapellier","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0035","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2127691","article-title":"A newly discovered PD - L1 B - cell epitope peptide vaccine (PDL1 - Vaxx) exhibits potent immune responses and effective anti - tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER - 2 B - cell vaccine (B - Vaxx)","volume":"11","author":"Guo","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0036","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005491","article-title":"TGF\u03b2 - derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer","volume":"10","author":"Perez-Penco","year":"2022","journal-title":"J. Immunother. Cancer."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0037","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3390\/cancers14061550","article-title":"Mesothelin: an immunotherapeutic target beyond solid tumors","volume":"14","author":"Faust","year":"2022","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.seminoncol.2025.152399_bib0038","article-title":"Targeting Mesothelin enhances personalized neoantigen vaccine induced antitumor immune response in orthotopic pancreatic cancer mouse models","volume":"12","author":"Cai","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0039","article-title":"Mesothelin virus - like particle immunization controls pancreatic cancer growth through CD8+ T cell induction and reduction in the frequency of CD4+ foxp3+ ICOS - regulatory T cells","volume":"8","author":"Zhang","year":"2013","journal-title":"PloS one"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0040","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/1521-4141(200203)32:3<818::AID-IMMU818>3.0.CO;2-U","article-title":"Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP","volume":"32","year":"2002","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0041","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","article-title":"Activity of Mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial","volume":"155","author":"Beatty","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0042","unstructured":"Mesothelin-targeted CAR T-cell Therapy safe, Shows Early Promise in Patients With Advanced Solid Tumors. https:\/\/www.targetedonc.com\/view\/mesothelintargeted-car-tcell-therapy-shows-early-efficacy-in-advanced-solid-cancers."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0043","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3390\/biomedicines9040397","article-title":"Mesothelin expression in Human tumors: a tissue microarray study on 12,679 tumors","volume":"9","author":"Weidemann","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0044","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1042\/BST20170400","article-title":"Latest developments in MUC1 immunotherapy","volume":"46","author":"Taylor-Papadimitriou","year":"2018","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0045","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s11658-024-00654-x","article-title":"Research progress of MUC1 in genitourinary cancers","volume":"29","author":"Mao","year":"2024","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0046","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.molmed.2019.10.003","article-title":"Microbe-MUC1 crosstalk in cancer-associated infections","volume":"26","author":"Bose","year":"2020","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0047","first-page":"79","article-title":"Targeted immunotherapy designed to treat MUC1-expressing solid tumour","volume":"405","author":"Acres","year":"2017","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0048","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/00000478-200407000-00001","article-title":"Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an \u201cintestinal\u201d pathway of carcinogenesis in the pancreas","volume":"28","author":"Adsay","year":"2004","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0049","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3390\/biom15020275","article-title":"The oncoprotein mucin 1 in pancreatic cancer onset and progression: potential clinical implications","volume":"15","author":"Dieli","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0050","first-page":"107","article-title":"Expression and localization of MUC1, MUC2, MUC5AC and small intestinal mucin antigen in pancreatic tumors","volume":"24","author":"Yamasaki","year":"2004","journal-title":"Int J Oncol"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0051","first-page":"955","article-title":"A phase I\/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors","volume":"6","author":"Lepisto","year":"2006","journal-title":"Cancer Ther"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0052","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1080\/1120009X.2023.2282839","article-title":"Advances in MUC1 resistance to chemotherapy in pancreatic cancer","volume":"36","author":"Yao","year":"2024","journal-title":"J Chemother"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0053","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(15)00483-0","article-title":"TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b\/3 trial","volume":"17","author":"Quoix","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0054","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.3390\/pharmaceutics15122774","article-title":"Enhancing T cell and antibody response in mucin-1 transgenic mice through Co-delivery of tumor-associated mucin-1 antigen and TLR agonists in C3-liposomes","volume":"15","author":"Arabi","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0055","doi-asserted-by":"crossref","first-page":"54","DOI":"10.7150\/jca.88261","article-title":"Mucin1 as a potential molecule for cancer immunotherapy and targeted therapy","volume":"15","author":"Tong","year":"2024","journal-title":"J. Cancer"},{"issue":"37","key":"10.1016\/j.seminoncol.2025.152399_bib0056","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202407131","article-title":"Detection of tumor - associated autoantibodies in the sera of pancreatic cancer patients using engineered MUC1 glycopeptide nanoparticle probes","volume":"63","author":"Corzana","year":"2024","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0057","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1080\/10428194.2016.1195500","article-title":"MUC1 in hematological malignancies","volume":"57","author":"Stroopinsky","year":"2016","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152399_bib0058","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085155","article-title":"Telomerase inhibitor Imetelstat (GRN163L) limits the lifespan of human pancreatic cancer cells","volume":"9","author":"Burchett","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0059","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/sj.bjc.6604209","article-title":"Targeting telomerase for cancer therapeutics","volume":"98","author":"Shay","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0060","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/sj.bjc.6603437","article-title":"Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I\/II study","volume":"95","author":"Bernhardt","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0061","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1038\/s41388-020-01405-w","article-title":"Targeting telomerase for cancer therapy","volume":"39","author":"Guterres","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0062","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S1470-2045(14)70236-0","article-title":"Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial","volume":"15","author":"Middleton","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0063","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.901277","article-title":"GM-CSF: a double-edged sword in cancer immunotherapy","volume":"13","author":"Kumar","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0064","doi-asserted-by":"crossref","first-page":"e242","DOI":"10.1038\/emm.2016.64","article-title":"Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types","volume":"48","author":"Hong","year":"2016","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0065","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41416-023-02474-w","article-title":"Efficacy of GV1001 with gemcitabine\/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4\/2015): an open-label, randomised, phase 3 trial","volume":"130","author":"Jo","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0066","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0067","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.3390\/cancers16162876","article-title":"Precision targeting strategies in pancreatic cancer: the role of tumor microenvironment","volume":"16","author":"Vitorakis","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0068","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.ccell.2024.08.001","article-title":"The KRAS mutational spectrum and its clinical implications in pancreatic cancer","volume":"42","author":"Perelli","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0069","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3892\/or.2023.8643","article-title":"Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: recent advancements provide hope (Review)","volume":"50","author":"Zhang","year":"2023","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0070","doi-asserted-by":"crossref","unstructured":"M.F. Lansbergen, J. Koster, et al. KRAS mutation status integrated with RNA subtyping improves prognostic modeling in FOLFIRINOX-treated metastatic pancreatic cancer. Med (New York, N.Y.) vol. 6,6 (2025): 100601. doi:10.1016\/j.medj.2025.100601.","DOI":"10.1016\/j.medj.2025.100601"},{"issue":"2010","key":"10.1016\/j.seminoncol.2025.152399_bib0071","article-title":"Targeting the tumor microenvironment: an unexplored strategy for mutant KRAS tumors","volume":"11","author":"Dias Carvalho","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0072","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13045-024-01631-9","article-title":"RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms","volume":"17","author":"Yang","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0073","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1158\/2326-6066.CIR-15-0188","article-title":"Identification of T-cell receptors targeting KRAS-mutated Human tumors","volume":"4","author":"Wang","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0074","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.canlet.2020.06.011","article-title":"Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC)","volume":"490","author":"Chen","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113147","article-title":"Proteogenomics offers a novel avenue in neoantigen identification for cancer immunotherapy","volume":"142","author":"Ren","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0076","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1038\/s41467-021-24562-2","article-title":"Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting","volume":"12","author":"Bear","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0077","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/d41573-021-00147-y","article-title":"Evolution of the market for mRNA technology","volume":"20","author":"Xie","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0078","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0079","doi-asserted-by":"crossref","first-page":"e492","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials on mRNA vaccines for cancer treatment","volume":"23","author":"Lorentzen","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0080","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","article-title":"The clinical progress of mRNA vaccines and immunotherapies","volume":"40","author":"Barbier","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0081","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0082","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-cell transfer therapy targeting mutant KRAS in cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"btae205","key":"10.1016\/j.seminoncol.2025.152399_bib0083","article-title":"NeoAgDT: optimization of personal neoantigen vaccine composition by digital twin simulation of a cancer cell population","volume":"40","author":"M\u00f6sch","year":"2024","journal-title":"Bioinformatics (Oxford, England)"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0084","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2300881","article-title":"Establishment of a novel tumor neoantigen prediction tool for personalized vaccine design","volume":"20","author":"Xin","year":"2024","journal-title":"Human vaccines & immunotherapeutics"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0085","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1109\/TCBB.2021.3074927","article-title":"DeepSeqPanII: an interpretable recurrent neural network model with attention mechanism for peptide-HLA II binding prediction","volume":"19","author":"Liu","year":"2022","journal-title":"IEEE\/ACM Trans. Comput. Biol. Bioinform."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0086","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1158\/1078-0432.CCR-19-2881","article-title":"A pan-cancer clinical study of personalized neoantigen vaccine monotherapy in treating patients with various types of advanced solid tumors","volume":"26","author":"Fang","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0087","article-title":"A neoantigen-based peptide vaccine for patients with advanced pancreatic cancer refractory to standard treatment","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0088","article-title":"Prognostic indicators of KRAS G12X mutations in pancreatic cancer","volume":"41","author":"Bach","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0089","doi-asserted-by":"crossref","first-page":"eabe5819","DOI":"10.1126\/sciadv.abe5819","article-title":"A lymph node - targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS - CoV - 2","volume":"7","author":"Steinbuck","year":"2021","journal-title":"Science advances"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0090","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","article-title":"Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial","volume":"30","author":"Pant","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.seminoncol.2025.152399_sbref0091","series-title":"Elicio therapeutics reaches alignment with FDA on ELI-002 registrational strategy. News release","year":"2025"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0092","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04853017."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0093","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1200\/JCO.2014.57.4244","article-title":"Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer","volume":"33","author":"Le","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0094","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3390\/ph14070677","article-title":"Hacking pancreatic cancer: present and future of personalized medicine","volume":"14","author":"Di Federico","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0095","doi-asserted-by":"crossref","first-page":"5493","DOI":"10.1158\/1078-0432.CCR-18-2992","article-title":"Results from a phase IIb, randomized, multicenter study of GVAX Pancreas and CRS-207 compared with chemotherapy in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study)","volume":"25","author":"Le","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0096","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2022.40.4_suppl.558","article-title":"Neoadjuvant and adjuvant antitumor vaccination alone or combination with PD1 blockade and CD137 agonism in patients with resectable pancreatic adenocarcinoma","volume":"40","author":"Heumann","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0097","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1038\/s41467-023-39196-9","article-title":"A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma","volume":"14","author":"Heumann","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0098","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1158\/1078-0432.CCR-20-1025","article-title":"A phase II study of allogeneic GM-CSF-transfected pancreatic tumor vaccine (GVAX) with Ipilimumab as maintenance treatment for metastatic pancreatic cancer","volume":"26","author":"Wu","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0099","article-title":"A phase 2 study of cyclophosphamide (CY), GVAX, pembrolizumab (Pembro), and stereotactic body radiation (SBRT) in patients (pts) with locally advanced pancreas cancer (LAPC)","volume":"39","author":"Valerie","year":"2021","journal-title":"JCO"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0100","doi-asserted-by":"crossref","first-page":"eadk1827","DOI":"10.1126\/sciadv.adk1827","article-title":"Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells","volume":"10","author":"Wang","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0101","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04161755"},{"issue":"6","key":"10.1016\/j.seminoncol.2025.152399_bib0102","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/s43018-024-00756-7","article-title":"PERCEPTION predicts patient response and resistance to treatment using single - cell transcriptomics of their tumors","volume":"5","author":"Sinha","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0103","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3390\/jfb15080229","article-title":"Mannan - decorated lipid calcium phosphate nanoparticle vaccine increased the antitumor immune response by modulating the tumor microenvironment","volume":"15","author":"Wu","year":"2024","journal-title":"J. Funct. Biomater."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0104","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12943-021-01467-8","article-title":"Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion","volume":"20","author":"Cai","year":"2021","journal-title":"Mol. Cancer."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0105","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41392-024-01953-7","article-title":"Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0106","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1200\/JCO.23.02585","article-title":"Dendritic cell-based immunotherapy in patients with resected pancreatic cancer","volume":"42","author":"van 't Land","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0107","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s00268-004-7817-2","article-title":"Roles of thymosins in cancers and other organ systems","volume":"29","author":"Chen","year":"2005","journal-title":"World J. Surg."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0108","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/978-1-62703-287-2_9","article-title":"Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine","volume":"980","author":"Laheru","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0109","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1038\/s41467-023-40886-7","article-title":"Metabolic glycan labeling immobilizes dendritic cell membrane and enhances antitumor efficacy of dendritic cell vaccine","volume":"14","author":"Han","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0110","doi-asserted-by":"crossref","first-page":"26770","DOI":"10.1021\/acsnano.4c07360","article-title":"Carbohydrate-lectin interactions reprogram dendritic cells to promote type 1 anti-tumor immunity","volume":"18","author":"Lensch","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0111","doi-asserted-by":"crossref","first-page":"6864","DOI":"10.3390\/curroncol29100541","article-title":"The role of immunotherapy in pancreatic cancer","volume":"29","author":"Mukherji","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0112","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.3007","article-title":"Effect of algenpantucel-L immunotherapy for pancreatic cancer on anti-mesothelin antibody (Ab) titers and correlation with improved overall survival","volume":"31","author":"Rossi","year":"2013","journal-title":"JCO"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0113","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/SLA.0000000000004669","article-title":"A phase 3 randomized clinical trial of chemotherapy with or without Algenpantucel-L (HyperAcute-Pancreas) immunotherapy in subjects with borderline resectable or locally advanced unresectable pancreatic cancer","volume":"275","author":"Hewitt","year":"2022","journal-title":"Ann. Surg."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0114","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41392-024-02031-8","article-title":"Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase ib\/II trial","volume":"9","author":"Cheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0115","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.immuni.2018.03.037","article-title":"TGF-\u03b2 inhibition and immunotherapy: checkmate","volume":"48","author":"Ganesh","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0116","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2024.101012","article-title":"Real-world outcomes of FR\u03b1 targeting treatment with Mirv In Chinese proc patients [J]","volume":"35","author":"Li","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0117","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4251\/wjgo.v12.i2.173","article-title":"Pancreatic ductal adenocarcinoma: treatment hurdles, tumor microenvironment and immunotherapy","volume":"12","author":"Sarantis","year":"2020","journal-title":"World J. Gastrointest. Oncol."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0118","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ags3.12176","article-title":"Immunotherapy for pancreatic cancer: barriers and breakthroughs","volume":"2","author":"Torphy","year":"2018","journal-title":"Ann. Gastroenterol. Surg."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0119","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4251\/wjgo.v12.i2.173","article-title":"Pancreatic ductal adenocarcinoma: treatment hurdles, tumor microenvironment and immunotherapy","volume":"12","author":"Sarantis","year":"2020","journal-title":"World J. Gastrointest. Oncol."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0120","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1479-5876-5-60","article-title":"Poxvirus - based vaccine therapy for patients with advanced pancreatic cancer","volume":"5","author":"Kaufman","year":"2007","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0121","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.3390\/cancers13153738","article-title":"Gemcitabine plus nab - paclitaxel induces PD - L1 mRNA expression in plasma - derived microvesicles in pancreatic cancer","volume":"13","author":"Del Re","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0122","first-page":"657","article-title":"Multi-omics analysis of metastatic pancreatic cancer reveals an immunosuppressive landscape","volume":"4","author":"Steele","year":"2023","journal-title":"Med (N.Y.)"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0123","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1080\/1744666X.2022.2120471","article-title":"Combination immunotherapy for pancreatic cancer: challenges and future considerations","volume":"18","author":"G\u00f6ssling","year":"2022","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0124","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1186\/s12885-018-4453-z","article-title":"A phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer","volume":"18","author":"Hirooka","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100793","article-title":"PEGPH20, a PEGylated human hyaluronidase, induces radiosensitization by reoxygenation in pancreatic cancer xenografts. A molecular imaging study","volume":"30","author":"Seki","year":"2022","journal-title":"Neoplasia"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0126","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.3390\/cancers13061440","article-title":"CTLA-4 in regulatory T cells for cancer immunotherapy","volume":"13","author":"Sobhani","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0127","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10238-011-0159-0","article-title":"A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer","volume":"12","author":"Rong","year":"2012","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0128","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11605-012-2064-6","article-title":"Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study","volume":"17","author":"Hardacre","year":"2013","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0129","unstructured":"http:\/\/clinicaltrials.gov\/study\/NCT00569387."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0130","unstructured":"http:\/\/clinicaltrials.gov\/study\/NCT02004262."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0131","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1200\/JCO.2014.57.4244","article-title":"Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer","volume":"33","author":"Le","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0132","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/intimm\/dxl059","article-title":"Dendritic cells pulsed with alpha-galactosylceramide induce anti-tumor immunity against pancreatic cancer in vivo","volume":"18","author":"Nagaraj","year":"2006","journal-title":"Int Immunol"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0133","first-page":"2217","article-title":"WT1-pulsed dendritic cell vaccine combined with chemotherapy for resected pancreatic cancer in a phase I study","volume":"38","author":"Yanagisawa","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0134","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000772","article-title":"Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model","volume":"8","author":"Lau","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0135","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1007\/s10620-006-9205-2","article-title":"A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma","volume":"52","author":"Maki","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0136","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.stemcr.2021.04.004","article-title":"Antitumor effects of iPSC-based cancer vaccine in pancreatic cancer","volume":"16","author":"Ouyang","year":"2021","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0137","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.3892\/ol.2017.5717","article-title":"Optimized construction of MUC1-VNTRn DNA vaccine and its anti-pancreatic cancer efficacy","volume":"13","author":"Gong","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0138","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1038\/s41467-023-40207-y","article-title":"Generation of whole tumor cell vaccine for on-demand manipulation of immune responses against cancer under near-infrared laser irradiation","volume":"14","author":"Meng","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0139","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/1471-2407-12-361","article-title":"Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer","volume":"12","author":"Niethammer","year":"2012","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152399_bib0140","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1303584","article-title":"A phase 1 trial extension to assess immunologic efficacy and safety of prime - boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer","volume":"7","author":"Schmitz-Winnenthal","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0141","unstructured":"http:\/\/clinicaltrials.gov\/study\/NCT03948763."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0142","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1001\/jamasurg.2016.2346","article-title":"Pancreatic cancer cell lysis by cell-penetrating peptide-MAGE-A3-induced cytotoxic T lymphocytes","volume":"151","author":"Batchu","year":"2016","journal-title":"JAMA Surg"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0143","article-title":"A neoantigen-based peptide vaccine for patients with advanced pancreatic cancer refractory to standard treatment","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0144","volume":"11","author":"Gao","year":"2024"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0145","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","article-title":"Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial","volume":"30","author":"Pant","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0146","unstructured":"Maintenance OSE2101 plus FOLFIRI meets primary OSEnd point in advanced\/metastatic PDAG"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0147","article-title":"OSE Immunotherapeutics and GERCOR announce positive topline phase 2 result for clinical trial TEDOPaM evaluating OSE2101 (Tedopi\u00ae) in advanced pancreatic cancer. News release","year":"2025","journal-title":"OSE Immunotherapeutics SA"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0148","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/cas.12046","article-title":"Immunotherapeutic benefit of \u03b1-interferon (IFN\u03b1) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients","volume":"104","author":"Kameshima","year":"2013","journal-title":"Cancer Sci"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0149","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/MPA.0b013e31822ade7e","article-title":"An international multicenter randomized controlled trial of G17DT in patients with pancreatic cancer","volume":"41","author":"Gilliam","year":"2012","journal-title":"Pancreas"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0150","unstructured":"http:\/\/clinicaltrials.gov\/study\/NCT03200821."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0151","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.omto.2022.07.008","article-title":"CAFs\/tumor cells co-targeting DNA vaccine in combination with low-dose gemcitabine for the treatment of Panc02 murine pancreatic cancer","volume":"26","author":"Geng","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0152","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1089\/pancan.2020.0021","article-title":"A phase 2 randomized placebo-controlled adjuvant trial of GI-4000, a recombinant yeast expressing mutated RAS proteins in patients with resected Pancreas cancer","volume":"7","author":"Muscarella","year":"2021","journal-title":"J Pancreat Cancer"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0153","unstructured":"http:\/\/clinicaltrials.gov\/study\/NCT00844649."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0154","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41422-019-0195-y","article-title":"Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma","volume":"29","author":"Peng","year":"2019","journal-title":"Cell Res"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0155","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ccell.2023.01.001","article-title":"Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0156","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13073-019-0666-2","article-title":"Best practices for bioinformatic characterization of neoantigens for clinical utility","volume":"11","author":"Richters","year":"2019","journal-title":"Genome Med"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0157","article-title":"A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy","author":"Huber","year":"2024","journal-title":"Nat. Biotechnol."},{"issue":"42","key":"10.1016\/j.seminoncol.2025.152399_bib0158","doi-asserted-by":"crossref","first-page":"73098","DOI":"10.18632\/oncotarget.20392","article-title":"Prognostic value of c - met overexpression in pancreatic adenocarcinoma: a meta - analysis","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0159","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1186\/s12943-024-02184-8","article-title":"Chimeric antigen receptor macrophages targeting c - MET(CAR - M - c - MET) inhibit pancreatic cancer progression and improve cytotoxic chemotherapeutic efficacy","volume":"23","author":"Zheng","year":"2024","journal-title":"Mol. Cancer."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0160","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.bmc.2019.02.014","article-title":"4,6-Substituted-1H-indazoles as potent IDO1\/TDO dual inhibitors","volume":"27","author":"Yang","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0161","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/cas.14797","article-title":"Tryptophan 2,3-dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma","volume":"112","author":"Sumitomo","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0162","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/cbdd.13122","article-title":"Amphiphilic small peptides for delivery of plasmid DNAs and siRNAs","volume":"91","author":"Bang","year":"2018","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0163","article-title":"A versatile strategy to transform cationic polymers for efficient and organ - selective mRNA delivery","volume":"64","author":"Lin","year":"2025","journal-title":"Angew. Chem. Int. Ed."},{"issue":"19","key":"10.1016\/j.seminoncol.2025.152399_bib0164","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0165","article-title":"Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta - analysis","volume":"14","author":"Zhao","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0166","doi-asserted-by":"crossref","first-page":"143","DOI":"10.21037\/jgo.2018.01.13","article-title":"Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response","volume":"9","author":"Rosenberg","year":"2018","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0167","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.immuni.2023.09.002","article-title":"Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction","volume":"56","author":"M\u00fcller","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.seminoncol.2025.152399_bib0168","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202410998","article-title":"A polymeric mRNA vaccine featuring enhanced site - specific mRNA delivery and inherent STING - stimulating performance for tumor immunotherapy","volume":"37","author":"Guo","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0169","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1021\/acs.molpharmaceut.3c00846","article-title":"Advances in nanoplatforms for immunotherapy applications targeting the tumor microenvironment","volume":"21","author":"Zhang","year":"2024","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0170","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/nm.3973","article-title":"Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids","volume":"21","author":"Huang","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0171","doi-asserted-by":"crossref","first-page":"26580","DOI":"10.1073\/pnas.1911273116","article-title":"Pancreatic cancer organoids recapitulate disease and allow personalized drug screening","volume":"116","author":"Driehuis","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.seminoncol.2025.152399_bib0172","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41586-024-07892-1","article-title":"Closed-loop transfer enables artificial intelligence to yield chemical knowledge","volume":"633","author":"Angello","year":"2024","journal-title":"Nature"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775425000910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775425000910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T12:01:39Z","timestamp":1755950499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775425000910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":172,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0093775425000910"],"URL":"https:\/\/doi.org\/10.1016\/j.seminoncol.2025.152399","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Application prospects of tumor vaccines for pancreatic cancer: From TAAs to TSAs and combination strategies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seminoncol.2025.152399","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152399"}}